We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Synthetic Virus Designed to Enhance Delivery of New Generation of Pharmaceutical Agents

By LabMedica International staff writers
Posted on 10 Sep 2014
Print article
Image: Design of the minimal viral coat protein C-Sn-B (Photo courtesy of Wageningen University).
Image: Design of the minimal viral coat protein C-Sn-B (Photo courtesy of Wageningen University).
Dutch scientists have effectively developed an artificial virus that may be used for the delivery of a new generation of pharmaceutical agents, consisting of large biomolecules, by packaging them in a natural manner and delivering them to diseased cells. The artificial virus was developed according to a new theoretic determination of how viruses work, according to the researchers.

The findings were published in the August 31, 2014, issue of the journal Nature Nanotechnology. Specifically, the researchers, from Wageningen University (The Netherlands), along with colleagues from the University of Leiden (The Netherlands), Eindhoven University of Technology (The Netherlands), and Radboud University Nijmegen (The Netherlands) think that the artificial virus technology could be useful for gene therapy.

Standard drugs consist of comparatively small molecules that typically arrive at the desired location without too much difficulty. This is more difficult for newer types of drugs that are being developed; these are comprised of large biomolecules such as proteins and genetic material (i.e., DNA and RNA). For example, to use DNA in gene therapy, the molecule must be delivered to diseased cells in its totality to be effective. However, DNA is inherently incapable of penetrating cells and is rapidly degraded. Therefore natural viruses that have been rendered harmless are used as so-called vectors. These can enter cells efficiently and deliver the therapeutic DNA or RNA molecules.

However, the process of rendering natural viruses harmless still requires improvement. Unwanted side effects have been a hurdle. Therefore, research is also being conducted into alternative virus-like vectors based on synthetic molecules. Regrettably, these have been less effective because it is difficult to precisely duplicate the many behaviors used by viruses. A first important step in mimicking viruses is the effective packaging of individual DNA molecules with a protective coat of smaller molecules. This sounds easier than it is, the researchers reported. Up to now, packing individual DNA molecules with a protective coating of synthetic molecules has not yet been accomplished.

The researchers decided to design and construct artificial viral coat proteins, instead of using synthetic chemistry to coat individual DNA molecules. As part of their study, they used recent theoretic insights into the key aspects of the process of packaging genetic material by natural viral coat proteins. The researchers converted each of these key features into various protein blocks with simple structures. The amino acid sequence of the protein blocks was inspired by natural proteins such as collagen and silk. Artificial viral coat proteins designed in this manner were produced using the natural processes of yeast cells. When the proteins were combined with DNA, they spontaneously formed a highly protective protein coat around each DNA molecule, thus creating artificial viruses. The formation process of the artificial viruses is similar in many ways to that of natural viruses, such as the tobacco mosaic virus, which served as a model for the artificial virus.

This first generation of artificial viruses was found to be as effective as the current methods for delivering DNA to host cells based on synthetic molecules. But the great precision by which DNA molecules are packaged in the artificial virus offers many possibilities to now also build in other virus tricks, the researchers write. In the future, these techniques can hopefully lead to safe and effective approaches for delivering new generations of pharmaceuticals, especially in gene therapy. Moreover, these artificial viruses can also be developed for the many other applications in which viruses are now being used in fields such as biotechnology and nanotechnology.

The artificial viral proteins were designed and produced by scientists of Wageningen UR (University & Research Center). They worked in collaboration with colleagues from Eindhoven University of Technology and Leiden University, who provided contributions based on the theory of spontaneous formation of virus particles, and helped to visualize the resulting artificial virus particles, and partners from Radboud University Nijmegen, who assessed the penetration of the artificial virus particles into living cells.

Related Links:

Wageningen University
University of Leiden 
Radboud University Nijmegen 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.